
Helene F. S. Negaard
- Consultant oncologist; MD, PhD
- +47 23 02 78 45
Publications 2020
Metachronous Contralateral Testicular Cancer in the Cisplatin Era: A Population-Based Cohort Study
J Clin Oncol, JCO2002713 (in press)
DOI 10.1200/JCO.20.02713, PubMed 33356420
Thromboembolic events after high-intensity training during cisplatin-based chemotherapy for testicular cancer: Case reports and review of the literature
Int J Cancer, 147 (11), 3189-3198
DOI 10.1002/ijc.33151, PubMed 32525564
Publications 2019
Surgical Complications in Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumour: A Population-based Study from the Swedish Norwegian Testicular Cancer Group
Eur Urol Oncol, 3 (3), 382-389
DOI 10.1016/j.euo.2019.08.002, PubMed 31506250
Continuing increased risk of second cancer in long-term testicular cancer survivors after treatment in the cisplatin era
Int J Cancer, 147 (1), 21-32
DOI 10.1002/ijc.32704, PubMed 31597192
Publications 2013
Evidence for long-term hypercoagulopathy, but normalization of markers of extracellular matrix turnover, in patients with non-Hodgkin lymphoma
Leuk Lymphoma, 56 (8), 2479-81
DOI 10.3109/10428194.2013.803227, PubMed 23656198
Publications 2011
Associations between regulators of extracellular matrix and hemostatic factors in hematologic neoplasias
Leuk Lymphoma, 52 (6), 1157-9
DOI 10.3109/10428194.2011.563886, PubMed 21463121
Publications 2009
Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas
Leuk Lymphoma, 50 (6), 998-1004
DOI 10.1080/10428190902889270, PubMed 19373600
Publications 2008
Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors
Leukemia, 23 (1), 162-9
DOI 10.1038/leu.2008.255, PubMed 18800145
Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor
Thromb Haemost, 99 (6), 1040-8
DOI 10.1160/TH07-09-0541, PubMed 18521506
Increased acquired activated protein C resistance in unselected patients with hematological malignancies
J Thromb Haemost, 6 (9), 1482-7
DOI 10.1111/j.1538-7836.2008.03060.x, PubMed 18573186
Publications 2006
Decreased lung cancer survival with hormone-replacement therapy: caused by a decreased tissue factor pathway inhibitor level?
J Clin Oncol, 24 (17), 2683-4; author reply 2684
DOI 10.1200/JCO.2006.06.4345, PubMed 16763285